2. Search Result
Search Result
Results for "

Auristatin E

" in MedChemExpress (MCE) Product Catalog:

65

Inhibitors & Agonists

4

Fluorescent Dye

4

Biochemical Assay Reagents

4

Inhibitory Antibodies

3

Isotope-Labeled Compounds

1

Antibodies

3

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15582
    Auristatin E

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin.
    <em>Auristatin</em> <em>E</em>
  • HY-145989S
    Aminobenzenesulfonic auristatin E-d8

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].
    Aminobenzenesulfonic <em>auristatin</em> <em>E</em>-d8
  • HY-145989A
    Aminobenzenesulfonic auristatin E TFA

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic <em>auristatin</em> <em>E</em> TFA
  • HY-15582G
    Auristatin E

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin E (GMP) is Auristatin E (HY-15582) produced by using GMP guidelines. Auristatin E is a tubulin polymerization inhibitor .
    Auristatin E
  • HY-145989
    Aminobenzenesulfonic auristatin E

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
    Aminobenzenesulfonic <em>auristatin</em> <em>E</em>
  • HY-33048
    Monomethyl auristatin E intermediate-1

    		Others Cancer
    Monomethyl auristatin E intermediate-1 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-1
  • HY-43146
    Monomethyl auristatin E intermediate-3

    		Others Cancer
    Monomethyl auristatin E intermediate-3 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-3
  • HY-43147
    Monomethyl auristatin E intermediate-4

    		Others Cancer
    Monomethyl auristatin E intermediate-4 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-4
  • HY-43149
    Monomethyl auristatin E intermediate-5

    		Others Cancer
    Monomethyl auristatin E intermediate-5 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-5
  • HY-49413
    Monomethyl auristatin E intermediate-2

    		Others Cancer
    Monomethyl auristatin E intermediate-2 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-2
  • HY-78899
    Monomethyl auristatin E intermediate-6

    		Others Cancer
    Monomethyl auristatin E intermediate-6 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-6
  • HY-78901
    Monomethyl auristatin E intermediate-7

    		Others Cancer
    Monomethyl auristatin E intermediate-7 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-7
  • HY-78901A
    Monomethyl auristatin E intermediate-8

    		Others Cancer
    Monomethyl auristatin E intermediate-8 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-8
  • HY-78903
    Monomethyl auristatin E intermediate-9

    		Others Cancer
    Monomethyl auristatin E intermediate-9 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-9
  • HY-78903A
    Monomethyl auristatin E intermediate-10

    		Others Cancer
    Monomethyl auristatin E intermediate-10 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-10
  • HY-78908
    Monomethyl auristatin E intermediate-11

    		Others Cancer
    Monomethyl auristatin E intermediate-11 is an intermediate reactant in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-11
  • HY-78910
    Monomethyl auristatin E intermediate-12

    		Others Cancer
    Monomethyl auristatin E intermediate-12 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-12
  • HY-78911
    Monomethyl auristatin E intermediate-13

    		Others Cancer
    Monomethyl auristatin E intermediate-13 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-13
  • HY-78913
    Monomethyl auristatin E intermediate-14

    		Others Cancer
    Monomethyl auristatin E intermediate-14 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-14
  • HY-79196
    Monomethyl auristatin E intermediate-15

    		Others Cancer
    Monomethyl auristatin E intermediate-15 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-15
  • HY-79198
    Monomethyl auristatin E intermediate-16

    		Others Cancer
    Monomethyl auristatin E intermediate-16 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-16
  • HY-79205
    Monomethyl auristatin E intermediate-17

    		Others Cancer
    Monomethyl auristatin E intermediate-17 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    Monomethyl <em>auristatin</em> <em>E</em> intermediate-17
  • HY-128899
    MC-Val-Cit-PAB-Auristatin E

    		Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-PAB-Auristatin E is a agent-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.
    MC-Val-Cit-PAB-<em>Auristatin</em> <em>E</em>
  • HY-15162G
    Monomethyl auristatin E

    MMAE; SGD-1010; Vedotin

    		 Microtubule/Tubulin Apoptosis ADC Cytotoxin Cancer
    Monomethyl auristatin E (MMAE) (GMP) is Monomethyl auristatin E (HY-15162) produced by using GMP guidelines. Monomethyl auristatin E is a tubulin polymerization inhibitor .
    Monomethyl auristatin E
  • HY-78899A
    (4R,5S)-Monomethyl auristatin E intermediate-6

    		Others Cancer
    (4R,5S)-Monomethyl auristatin E intermediate-6 is an intermediate reagent in the synthesis of Monomethyl auristatin E (HY-15162). Monomethyl auristatin E (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely used as the cytotoxic component (ADC Cytotoxin) of antibody-drug conjugates (ADCs) .
    (4R,5S)-Monomethyl <em>auristatin</em> <em>E</em> intermediate-6
  • HY-15162
    Monomethyl auristatin E
    35+ Cited Publications

    MMAE; SGD-1010; Vedotin

    		 Microtubule/Tubulin ADC Cytotoxin Apoptosis Cancer
    Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
    Monomethyl <em>auristatin</em> <em>E</em>
  • HY-100566
    SuO-Val-Cit-PAB-MMAE
    1 Publications Verification

    		 Drug-Linker Conjugates for ADC Cancer
    SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .
    SuO-Val-Cit-PAB-MMAE
  • HY-156712
    Depatuxizumab MMAE

    		Antibody-Drug Conjugates (ADCs) Cancer
    Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) and the cytotoxic agent Monomethyl auristatin E (MMAE). Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR .
    Depatuxizumab MMAE
  • HY-78931
    Boc-Dap-NE

    		ADC Linker Cancer
    Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    Boc-Dap-NE
  • HY-78931G
    Boc-Dap-NE

    		ADC Linker Cancer
    Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    Boc-Dap-NE
  • HY-78932
    Dap-NE

    		Others Cancer
    Dap-NE is an intermediate reagent in the synthesis of the ADC toxin Monomethyl auristatin E (HY-15162) .
    Dap-NE
  • HY-78931C
    (S,S,R,S,R)-Boc-Dap-NE

    		Others Cancer
    (S,S,R,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (S,S,R,S,R)-Boc-Dap-NE
  • HY-78931E
    (R,S,R,S,R)-Boc-Dap-NE

    		Others Cancer
    (R,S,R,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (R,S,R,S,R)-Boc-Dap-NE
  • HY-78931F
    (R,S,S,S,R)-Boc-Dap-NE

    		Others Cancer
    (R,S,S,S,R)-Boc-Dap-NE is an isomer of the dipeptide Boc-Dap-NE (HY-78931). Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (R,S,S,S,R)-Boc-Dap-NE
  • HY-78931A
    (R,S,S,R,S)-Boc-Dap-NE

    		Others Cancer
    (R,S,S,R,S)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (R,S,S,R,S)-Boc-Dap-NE
  • HY-78931B
    (S,S,S,S,R)-Boc-Dap-NE

    		Others Cancer
    (S,S,S,S,R)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (S,S,S,S,R)-Boc-Dap-NE
  • HY-141860
    PSMA-Val-Cit-PAB-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer.
    PSMA-Val-Cit-PAB-MMAE
  • HY-15741
    Mc-MMAE

    Maleimidocaproyl-monomethylAuristatin E

    		 Microtubule/Tubulin Drug-Linker Conjugates for ADC Cancer
    Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a agent-linker conjugate for ADC.
    Mc-MMAE
  • HY-78933
    Fmoc-MMAE

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Fmoc-MMAE can be used in the synthesis of ADC .
    Fmoc-MMAE
  • HY-153428
    GGGDTDTC-Mc-vc-PAB-MMAE

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    GGGDTDTC-Mc-vc-PAB-MMAE is a Drug-Linker Conjugate for ADC, containing a tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) .
    GGGDTDTC-Mc-vc-PAB-MMAE
  • HY-157284
    Cys-mc-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    Cys-mc-MMAE is a Drug-Linker Conjugates for ADC, and consists of Monomethyl auristatin E (HY-15162) and a linker. Cys-mc-MMAE can be used for synthesis of ADCs .
    Cys-mc-MMAE
  • HY-78738
    MC-Val-Cit-PAB

    		ADC Linker Cancer
    MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.
    MC-Val-Cit-PAB
  • HY-160702
    DMBA-SIL-Mal-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    DMBA-SIL-Mal-MMAE is a cytotoxin-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked DMBA-SIL-Mal .
    DMBA-SIL-Mal-MMAE
  • HY-126681
    SC-VC-PAB-MMAE
    1 Publications Verification

    		 Drug-Linker Conjugates for ADC Cancer
    SC-VC-PAB-MMAE is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .
    SC-VC-PAB-MMAE
  • HY-153976
    Fmoc-Gly3-VC-PAB-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    Fmoc-Gly3-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. Fmoc-Gly3-VC-PAB-MMAE consists of Monomethyl auristatin E (HY-15162) and a linker .
    Fmoc-Gly3-VC-PAB-MMAE
  • HY-15575
    VcMMAE
    Maximum Cited Publications
    44 Publications Verification

    MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
    VcMMAE
  • HY-15162A
    MMAE-d8
    5+ Cited Publications

    Monomethyl Auristatin E-d8; Deuterated labeled MMAE

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
    MMAE-d8
  • HY-126686
    Mal-Phe-C4-VC-PAB-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate.
    Mal-Phe-C4-VC-PAB-MMAE
  • HY-152916
    mp-dLAE-PABC-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    mp-dLAE-PABC-MMAE is a agent-linker conjugate for ADC. mp-dLAE-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (HY-15162). mp-dLAE-PABC-MMAE can be used to synthesis antibody-drug conjugates (ADCs) .
    mp-dLAE-PABC-MMAE
  • HY-P99593A
    Sofituzumab vedotin (solution)

    DMUC5754A (solution)

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .
    Sofituzumab vedotin (solution)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: